Octaplasma (Human Plasma Protein)

Human Plasma Protein in Octaplasma provides a balanced mix of all essential coagulation factors and plasma proteins. When infused, these components replenish depleted factors, reactivate the coagulation cascade, and support clot formation, thereby correcting coagulopathy and reducing bleeding.

The dose of Octaplasma is individualized. A prescribing clinician determines the volume and rate based on the patient’s weight, the severity of the coagulopathy, laboratory values, and the clinical situation. No standard dosing regimen is provided in public resources.

Octaplasma may be administered to pregnant or breastfeeding patients only when clearly needed and when the potential benefits outweigh any theoretical risks. Clinical judgment and specialist consultation are recommended, as data specific to these populations are limited.

To order Octaplasma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Octaplasma is a solvent/detergent‑treated pooled plasma product that offers standardized concentrations of clotting factors and reduced pathogen risk compared with FFP. Unlike FFP, which is derived from a single donor and may vary in factor levels, Octaplasma provides consistent dosing and a lower incidence of transfusion‑related reactions, though both serve similar clinical purposes.

Octaplasma must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to use, allow the product to reach room temperature if required by the administration protocol, and inspect for any discoloration or particulate matter.

Octaplasma is given as an intravenous infusion. The solution is administered through a dedicated IV line, typically using a controlled infusion pump or gravity drip, following institutional guidelines for rate and volume to avoid circulatory overload. Monitoring of vital signs and coagulation parameters is recommended during and after the infusion.

Serious risks include anaphylactic or severe allergic reactions, transfusion‑related acute lung injury (TRALI), severe hemolysis, and volume overload that can lead to pulmonary edema. Prompt recognition and management of these events are essential, and patients should be closely observed throughout the infusion.

Octaplasma should be avoided in patients with a documented severe allergy to plasma proteins or any component of the product, in those with uncontrolled volume overload, or in individuals with a history of severe transfusion reactions such as TRALI. Contra‑indications must be assessed by the treating physician before administration.